5-amino-1mq mechanism nnmt inhibitor TRANSCEND trial: Approved treatments are lacking for acquired hypothalamic obesity. New research findings on the efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, are summarized in a Quick Take video: https://nej.md/4eVGFg9 Wholesale AHK-CU + GHK-CU Volume:Single 5mg vial Cellular Research
Pay in 4 interest-free payments of $6.40 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17